Tropical spastic paraparesis pathophysiology: Difference between revisions
No edit summary |
m Changes made per Mahshid's request |
||
| Line 14: | Line 14: | ||
[[Category:Viral diseases]] | [[Category:Viral diseases]] | ||
[[Category:Neurology]] | [[Category:Neurology]] | ||
[[Category:Needs overview]] | [[Category:Needs overview]] | ||
[[Category:Needs content]] | [[Category:Needs content]] | ||
Latest revision as of 19:01, 18 September 2017
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
|
Tropical spastic paraparesis Microchapters |
|
Differentiating Tropical spastic paraparesis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Tropical spastic paraparesis pathophysiology On the Web |
|
American Roentgen Ray Society Images of Tropical spastic paraparesis pathophysiology |
|
Directions to Hospitals Treating Tropical spastic paraparesis |
|
Risk calculators and risk factors for Tropical spastic paraparesis pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Pathophysiology
When infected by HTLV-1[1] the host mounts an antigen specific immune response towards the HTLV-1 antigen. Cytotoxic T-lymphocytes of the host’s immune response release cytokines in an effort to fight the infection. These cytokines facilitate the transendothelial migration of lymphocytes across the blood-brain barrier. Once cytokines are within the central nervous system demyelination is brought as a result of bystander cell injury. The disease is chronic, progressing slowly, usually causing symptoms 20-30 years after infection.